EPIDEMIOLOGY Accurate, in-depth information for understanding and assessing targeted markets
WHY ACCURATE MARKET FORECASTS Start with accurate understanding Epidemiology is the study of disease patterns and the effects of disease in defined populations, including its prevalence, incidence and clinical history. For pharmaceutical and biotech companies, epidemiology is the foundation for building targeted drug development and commercialization programs. And to ensure the success of those programs, the epidemiology information used to build them has to be more than accurate. It has to be gold standard. DRG s epidemiological data and patient population forecasts are widely considered the industry s gold standard. They are designed to help you validate investments, benchmark your forecasts, and identify growth opportunities with transparent, accepted, and valued bottom-up patient-level projections and methodologies. Answer the right questions, at the right time Developing a deep understanding of a targeted market is a crucial first step when deciding whether or not to invest in drug research or commercialization. The epidemiology (EPI) component of DRG s Disease Insights offering provides key metrics to: Size market potential Profile patient segments Make confident business decisions based on accurate forecast models 2
WHAT DOES DRG EPI COVER? 150+ DISEASES 2,300 PATIENT POPULATIONS Data for 150+ diseases, representing approximately 2,300 patient populations and subpopulations, within such therapy areas as oncology, cardiovascular, central nervous system, ophthalmology, and autoimmune & inflammation, hematology, infectious diseases, and metabolic-renal 20-year projections for the 150+ diseases in the mature markets (G7 countries): the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan 10-year EPI data projections for approximately 60 diseases in emerging market countries, including Brazil, Russia, India, China, Mexico, Turkey, and South Korea Expanding coverage of regions such as the Americas, Europe (8 new countries), Asia Pacific (4 new countries) and Middle East/Africa Throughout 2016, we will be merging East Asia and South Asia & Pacific into a new region Asia Pacific. This region will also include new coverage in Hong Kong, Malaysia, Singapore, and New Zealand We will also be expanding our European coverage in Austria, Belgium, Denmark, Finland, Greece, Norway, Portugal and Switzerland 3
CONTENT YOU CAN BUILD ON All content in DRG s EPI offering undergoes an extensive selection and vetting process to insure accuracy and reliability. This process includes: 1. SYSTEMATIC LITERATURE SEARCH Our information is compiled from published secondary literature, primary data sources and DRG s extensive library featuring 300+ sources: Epidemiological data Pharmacoepidemiological estimates Demographic data 2. ASSESSMENT OF RELEVANCE The relevance of all DRG EPI information is appraised and curated according to: Market-relevant disease definition Age of source Sample representativeness Comprehensiveness Geographical extrapolation where country-specific data unavailable 3. PRELIMINARY FORECASTS Our primary forecasts assess the evolution of disease risk and burden: From time of data collection to base year Throughout the 10- to 20- year forecast period 4
4. FORECAST CONSIDERATIONS DRG EPI forecasts are subjected to the following considerations: Changes in exposure to protective or risk factors Improvements in survival Improvements in disease therapy Time between exposure to risk factors or therapies Risk of disease by gender and age group Changes in age structure and population size 5. BENCHMARKING AND VALIDATION Validation of DRG EPI information is carried out by comparing: Our estimates vs. publically available sources Prevalent, diagnosed, and drug-treated cases vs. published sales or other treatment data 6. PEER REVIEW As a final step in the process, the DRG expert epidemiology team provides a thorough forecast assessment, including: Preliminary forecast model Supporting evidence and rationale for choice of data sources Model assumptions 5
8 GOOD REASONS TO WORK WITH DRG EPI DATA QUALITY Our epidemiology data and patient population forecasts are widely considered the industry gold standard, with accepted patient-level, bottom-up approaches and transparent methodologies. FORECASTING Our bottoms-up forecasts offer 10- to 20-year projections and historical data upon request. Population predictions are based on disease risk factors, providing granularity beyond anticipated age and gender growth patterns. TRANSPARENCY All of our covered populations include downloadable methods and forecast assumptions in detail, as well as exhaustive background on disease definition and literature and data sources. PEOPLE DRG s established epidemiology team consists of highly skilled post-graduates and Ph.Ds, many with additional experience in public health, consultancies, CROs, market research, and academia. Our clients have direct access to our expert epidemiologists to address your specific questions and needs. 6
COVERAGE BREADTH Our therapeutic scope includes coverage of over 150 diseases in 20 detailed therapy areas. Geographic coverage of these diseases spans 50 unique countries across five continents. COVERAGE DEPTH Our patient-level data captures over 2,300 diagnosed and drug treated populations, also detailing segmentation by country, indication, year, age, gender, and subpopulations. TIMELINESS Our epidemiologists closely monitor the disease states that they own. And when a significant market event occurs, we work immediately to ensure that the impacted data is updated in a timely manner. REPUTATION With unparalleled epidemiology and patient population forecasts, a team of experts, and extensive market coverage, DRG has earned a position as a trusted partner in sizing market opportunities. 7
BENEFITS INTELLIGENCE YOU CAN ACT ON DRG s EPI offerings provide gold-standard data and insights for sizing market potential, segmenting patient populations, and making forecast-based business decisions. You can depend on our best-in-class population sizing data, tools, analytics, and expertise to give you the information you need to answer crucial questions such as: What is the size of a specific patient population across various geographies? What factors will drive growth in a specific patient population? Within a given patient population, how many cases are drug-treated? Which specific factors might influence future changes in drug-treatment? What are the age and gender details by indication? 8
OUR EXPERTS MEET OUR EXPERTS DRG s epidemiology team consists of highly skilled and superbly qualified post-graduates, MDs, and PhDs, many of whom also have deep expertise and experience in Academic Research, Public Health, Government Affairs, Policy, and Consulting. Here s a brief overview: 20+ epidemiologists with more than 170 years of combined experience A senior leadership team with 72 years combined experience Average of 5 years of outside work experience prior to joining DRG 9 team members in academia/research; 11 in public health; 3 in government/policy and 3 in industry or consulting 16 published papers/poster presentations produced in the last 12 months Members of the team are available to meet with clients via phone or email to discuss the EPI platform and answer any questions you may have about your current or potential projects. 9
EXPERTS THOUGHTS FIRST-HAND OBSERVATIONS We asked our epidemiology experts to tell us what they think about their experience with the EPI segment of DRG s Disease Insights offering. Here s what they had to say. It s got the same best-in-class data and insights our clients have come to expect, but in a sleek new format that makes it a pleasure to use. 10
The first thing I noticed was how intuitive it is so easy to navigate. I like the way the content is structured in modules. It makes it easy to view the data and the underlying context. Having all DRG EPI content available in a singleplatform makes it easier to cross-reference data points and find the information that I need. It saves time. With a single glance, I can view all the available coverage for a specific disease. 11
ASK DRG INSIGHTS PLATFORM: LAUNCHING MID-2016 Simple, modular and dynamic allowing you to select a custom package of research, data and analysis. KEY FEATURES INCLUDE: Google-like search functionality Complete customization to answer your key business questions Streamlined delivery of our best-in-class content in one location PLATFORM.DECISIONRESOURCESGROUP.COM QUESTIONS@TEAMDRG.COM US +1.855.380.4850 EU +44.20.7392.4100 APAC +81.03.5401.2615 DR / Decision Resources, LLC